Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE
Want to see SNSE full AI Analyst Report?
SNSE Stock Chart & Stats
$11.42
-$0.03(-5.03%)
At close: 4:00 PM EST
$11.42
-$0.03(-5.03%)
Day’s Range― - ―
52-Week Range$5.86 - $36.76
Previous CloseN/A
Volume8.76M
Average Volume (3M)38.93K
Market Cap
$17.45M
Enterprise Value-$122.92M
Total Cash (Recent Filing)$202.79M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Aug 11, 2026EPS Estimate
-5.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-147.90
Shares Outstanding1,341,941
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap-7.05
Enterprise Value/Revenue25.34
Enterprise Value/Gross Profit0.92
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$53.33Price Target Upside367.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-81.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Capitalization From Feb 2026 Private PlacementThe $200M PIPE tied to the Faeth acquisition materially increases near-term runway for clinical programs and reduces immediate financing pressure. That level of fresh capital supports Phase 2/1b/2 execution, enabling durable program advancement and partner-readiness over the next 2-6 months.
Experienced Oncology Leadership And Board AdditionsA consolidated leadership team with the Faeth founding CEO and an experienced oncology board including a former FDA commissioner strengthens regulatory navigation, clinical strategy and investor credibility. This durable governance upgrade can improve execution and trial design oversight long-term.
Focused Clinical-stage Lead Asset (PIKTOR) In Later-stage TrialsHaving PIKTOR in Phase 2 and Phase 1b/2 positions the company beyond early discovery, concentrating value creation on definable clinical readouts. Positive PIKTOR data would materially de-risk value, enable partnering/licensing, and shape market positioning over a multi-month to multi-year horizon.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow signal ongoing reliance on external financing to continue operations. Without product revenue, continued burn necessitates further capital raises to fund trials, increasing dilution risk and constraining strategic flexibility over the medium term.
Trailing-twelve-month Stockholders' Equity Turned NegativeNegative shareholders' equity weakens the balance sheet, limits borrowing capacity and undermines counterparties' confidence. This structural weakness elevates financing risk, can complicate partnerships or supplier terms, and heightens the likelihood of dilutive recapitalizations over time.
Major Authorized Share Increase And Series B Conversion RiskThe large authorized-share expansion and planned Series B conversion create a structural dilution pathway and potential change-of-control. This increases long-term dilution risk for existing holders, can alter governance incentives, and may depress per-share economics for future financings or partnerships.
Sensei Biotherapeutics News
SNSE FAQ
What was Sensei Biotherapeutics’s price range in the past 12 months?
Sensei Biotherapeutics lowest stock price was $5.86 and its highest was $36.76 in the past 12 months.
What is Sensei Biotherapeutics’s market cap?
Sensei Biotherapeutics’s market cap is $17.45M.
When is Sensei Biotherapeutics’s upcoming earnings report date?
Sensei Biotherapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 53 days.
How were Sensei Biotherapeutics’s earnings last quarter?
Sensei Biotherapeutics released its earnings results on May 15, 2026. The company reported -$131.45 earnings per share for the quarter, missing the consensus estimate of -$0.62 by -$130.83.
Is Sensei Biotherapeutics overvalued?
According to Wall Street analysts Sensei Biotherapeutics’s price is currently Undervalued.
Does Sensei Biotherapeutics pay dividends?
Sensei Biotherapeutics does not currently pay dividends.
What is Sensei Biotherapeutics’s EPS estimate?
Sensei Biotherapeutics’s EPS estimate is -5.05.
How many shares outstanding does Sensei Biotherapeutics have?
Sensei Biotherapeutics has 1,341,941 shares outstanding.
What happened to Sensei Biotherapeutics’s price movement after its last earnings report?
Sensei Biotherapeutics reported an EPS of -$131.45 in its last earnings report, missing expectations of -$0.62. Following the earnings report the stock price went up 3.078%.
Which hedge fund is a major shareholder of Sensei Biotherapeutics?
Currently, no hedge funds are holding shares in SNSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. This immunotherapy leverages bacteriophages to orchestrate a precise and robust innate and adaptive immune response. They also employ the Tumor Microenvironment Activated Biologics (TMAB) platform. This system is engineered to unleash T-cells' anti-tumor capabilities, utilizing human monoclonal antibodies specifically designed to operate within the tumor's immediate environment and target key immune checkpoints or other crucial signaling pathways. Sensei Biotherapeutics' pipeline features SNS-101, a monoclonal antibody developed for cancer therapy, and SNS-401-NG, an ImmunoPhage vaccine engineered to target a range of tumor antigens. Furthermore, they collaborate with The University of Washington on the research and development of a vaccine for Merkel cell carcinoma. Established in 1999, originally as Panacea Pharmaceuticals, Inc., Sensei Biotherapeutics maintains its headquarters in Rockville, Maryland.
SNSE Stock 12 Month Forecast
Average Price Target
$53.33
▲(367.02% Upside)
Technical Analysis
Cellectar Biosciences
―
Cocrystal Pharma
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Ownership Overview
53.09% Insiders
1.40% Mutual Funds
2.69% Other Institutional Investors
42.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---